Search research articles
Contact Us
Filters
Showing results (91-100 of 181) with videos related to
Page
of 19
Sort By:
Enfermedades Infecciosas Y Microbiologia Clinica
|
September 2, 2014
Costs and cost-efficacy analysis of the 2014 GESIDA/Spanish National AIDS Plan recommended guidelines for initial antiretroviral therapy in HIV-infected adults
Antonio Javier Blasco, Josep M Llibre, Juan Berenguer, et al.
AIDS (London, England)
|
August 6, 2015
Clinical value of ultradeep HIV-1 genotyping and tropism testing in late presenters with advanced disease
Maria Casadellà, Christian Manzardo, Marc Noguera-Julian, et al.
Antiviral Therapy
|
May 11, 2011
Nevirapine versus atazanavir/ritonavir, each combined with tenofovir disoproxil fumarate/emtricitabine, in antiretroviral-naive HIV-1 patients: the ARTEN Trial
Vicente Soriano, Keikawus Arastéh, Horacio Migrone, et al.
Sexually Transmitted Infections
|
May 11, 2022
Detecting anal human papillomavirus infection in men who have sex with men living with HIV: implications of assay variability
Montserrat Torres, Ana Silva-Klug, Elena Ferrer, et al.
The Journal of Infectious Diseases
|
October 13, 2020
No Changes in Human Immunodeficiency Virus (HIV) Suppression and Inflammatory Markers in Cerebrospinal Fluid in Patients Randomly Switched to Dolutegravir Plus Lamivudine (Spanish HIV/AIDS Research Network, PreEC/RIS 62)
Juan M Tiraboschi, Jhon Rojas, Henrik Zetterberg, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)
|
September 5, 2006
A once-daily lopinavir/ritonavir-based regimen provides noninferior antiviral activity compared with a twice-daily regimen
Margaret A Johnson, Joseph C Gathe, Daniel Podzamczer, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
June 8, 2006
Discontinuation of primary and secondary Toxoplasma gondii prophylaxis is safe in HIV-infected patients after immunological restoration with highly active antiretroviral therapy: results of an open, randomized, multicenter clinical trial
Jose M Miro, Juan C Lopez, Daniel Podzamczer, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)
|
October 5, 2013
Peak bone mass in young HIV-infected patients compared with healthy controls
Eugènia Negredo, Pere Domingo, Elena Ferrer, et al.
The Journal of Antimicrobial Chemotherapy
|
December 25, 2014
Atherogenic properties of lipoproteins in HIV patients starting atazanavir/ritonavir or darunavir/ritonavir: a substudy of the ATADAR randomized study
Maria Saumoy, Jordi Ordóñez-Llanos, Esteban Martínez, et al.
The Journal of Antimicrobial Chemotherapy
|
June 26, 2012
Simplification to dual antiretroviral therapy including a ritonavir-boosted protease inhibitor in treatment-experienced HIV-1-infected patients
Joaquin Burgos, Manuel Crespo, Vicenç Falcó, et al.
Page
of 19
Search research articles
Search
Showing results (91-100 of 181) with videos related to
Sort By:
Page
of 19
Enfermedades Infecciosas Y Microbiologia Clinica
|
September 2, 2014
Costs and cost-efficacy analysis of the 2014 GESIDA/Spanish National AIDS Plan recommended guidelines for initial antiretroviral therapy in HIV-infected adults
Antonio Javier Blasco, Josep M Llibre, Juan Berenguer, et al.
AIDS (London, England)
|
August 6, 2015
Clinical value of ultradeep HIV-1 genotyping and tropism testing in late presenters with advanced disease
Maria Casadellà, Christian Manzardo, Marc Noguera-Julian, et al.
Antiviral Therapy
|
May 11, 2011
Nevirapine versus atazanavir/ritonavir, each combined with tenofovir disoproxil fumarate/emtricitabine, in antiretroviral-naive HIV-1 patients: the ARTEN Trial
Vicente Soriano, Keikawus Arastéh, Horacio Migrone, et al.
Sexually Transmitted Infections
|
May 11, 2022
Detecting anal human papillomavirus infection in men who have sex with men living with HIV: implications of assay variability
Montserrat Torres, Ana Silva-Klug, Elena Ferrer, et al.
The Journal of Infectious Diseases
|
October 13, 2020
No Changes in Human Immunodeficiency Virus (HIV) Suppression and Inflammatory Markers in Cerebrospinal Fluid in Patients Randomly Switched to Dolutegravir Plus Lamivudine (Spanish HIV/AIDS Research Network, PreEC/RIS 62)
Juan M Tiraboschi, Jhon Rojas, Henrik Zetterberg, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)
|
September 5, 2006
A once-daily lopinavir/ritonavir-based regimen provides noninferior antiviral activity compared with a twice-daily regimen
Margaret A Johnson, Joseph C Gathe, Daniel Podzamczer, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
June 8, 2006
Discontinuation of primary and secondary Toxoplasma gondii prophylaxis is safe in HIV-infected patients after immunological restoration with highly active antiretroviral therapy: results of an open, randomized, multicenter clinical trial
Jose M Miro, Juan C Lopez, Daniel Podzamczer, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)
|
October 5, 2013
Peak bone mass in young HIV-infected patients compared with healthy controls
Eugènia Negredo, Pere Domingo, Elena Ferrer, et al.
The Journal of Antimicrobial Chemotherapy
|
December 25, 2014
Atherogenic properties of lipoproteins in HIV patients starting atazanavir/ritonavir or darunavir/ritonavir: a substudy of the ATADAR randomized study
Maria Saumoy, Jordi Ordóñez-Llanos, Esteban Martínez, et al.
The Journal of Antimicrobial Chemotherapy
|
June 26, 2012
Simplification to dual antiretroviral therapy including a ritonavir-boosted protease inhibitor in treatment-experienced HIV-1-infected patients
Joaquin Burgos, Manuel Crespo, Vicenç Falcó, et al.
Page
of 19